Article Text

Download PDFPDF
Letters to the editor
Authors' response to Pipeline, aneurysms and the FDA
  1. David F Kallmes1,
  2. Harry J Cloft1,
  3. David Fiorella2
  1. 1Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
  2. 2Department of Neurosurgery, State University of New York, Stony Brook, New York, USA
  1. Correspondence to Dr David F Kallmes, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA; kallmes.david{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We greatly appreciate the input by Dr Hirsch and colleagues.1 Our paper was a highly-focused empirical exercise to determine, based on morphology alone, the potential for endoluminal implants for treatment of aneurysms. There are myriad additional factors that, without question, will affect the appropriateness of …

View Full Text


  • Linked article 010326.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles